November 4, 2014 — Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of peripheral artery disease (PAD), at the Vascular Interventional Advances (VIVA) Annual Conference taking place Nov. 4-7 in Las Vegas.
Results of DISRUPT PAD will be presented by study principal investigator Marianne Brodmann, M.D., of the Medical University of Graz, Austria, on Wednesday, Nov. 5, during the Late-Breaking Trials Session taking place 8:10 to 9:34 a.m. PT.
In advanced vascular disease, atherosclerosis becomes calcified deep inside the vessel walls, limiting blood flow. These deposits are difficult to treat because they limit the effectiveness of current endovascular devices, making today’s interventions challenging and prone to both procedural and long-term failure. Lithoplasty is a novel balloon-based technology that utilizes integrated lithotripsy, a pulsatile mechanical energy commonly used to break up kidney stones, to disrupt both superficial and deep calcium and normalize vessel wall compliance prior to low-pressure balloon dilatation. Lithoplasty is designed to be naturally gentle to soft tissue (non-diseased portions of the vessel) while remaining hard on calcium, the tissue that limits vessel expansion and the effectiveness of current technologies.
For more information: www.shockwavemedical.com